Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178761 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL2182769 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178758 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178760 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178762 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178890 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178892 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL25143 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178895 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL17746959 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506970-A1 | COMPOUNDS WHICH CAN BLOCK THE RESPONSE TO CHEMICAL SUBSTANCES OR THERMAL STIMULI OR MEDIATORS OF INFLAMMATION OF NOCICEPTORS, PRODUCTION METHOD THEREOF AND COMPOSITIONS CONTAINING SAME | Diverdrugs, S.L. (ES) | 2005-02-16 | — | — | EP | claimed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7183430-B2 | Compounds which can block the response to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, production method thereof and compositions containing same | DIVERDRUGS, S.L. (ES) | 2007-02-27 | — | — | US | disclosed |
| US-20050130907-A1 | Compounds which can block the response to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, production method thereof and compositions containing same | BCN PEPTIDES S.A. (ES) | 2005-06-16 | — | — | US | disclosed |
| EP-1506970-A1 | COMPOUNDS WHICH CAN BLOCK THE RESPONSE TO CHEMICAL SUBSTANCES OR THERMAL STIMULI OR MEDIATORS OF INFLAMMATION OF NOCICEPTORS, PRODUCTION METHOD THEREOF AND COMPOSITIONS CONTAINING SAME | Diverdrugs, S.L. (ES) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130907-A1 | Compounds which can block the response to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, production method thereof and compositions containing same | OPRL1, TRPA1, LTB4R2 | KMT2A 3653/4885HTT 2217/4885EPHX2 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.